Name: Menarini Silicon Biosystems
Address: 10355 Science Center Dr # 210, San Diego, CA, 92121-1157, US
Telephone: (800) 381-4929

Menarini Silicon Biosystems, Inc. develops technologies and products that help to understand the biological complexity of disease through the study of single cells. Moving single-cell analysis from bench to bedside, the company is focused on fulfilling the vision of precision medicine — disease prevention and treatment that considers each person’s genetic variability. The company is a wholly owned subsidiary of The Menarini Group with a European facility in Bologna, Italy and U.S. headquarters in Huntingdon Valley, PA. Menarini Group with a heritage spanning 130 years and over 17,000 employees in more than 100 countries is a privately held multinational pharmaceutical, biotechnology and diagnostics company based in Florence, Italy.
The Company’s DEPArray™ System is the only automated instrument that can identify, quantify, and recover individual rare cells. Its DEPArray™ technology enables isolation of individual, intact cells, to study the biological significance of rare cells in disease development, progression, and therapeutic response. The DEPArray™ System can analyze samples containing from one to tens of thousands of cells and is compatible with a wide variety of rare cell suspensions, including live and fixed cells; enriched cells; and samples with small cell loads, such as fine needle aspirates and tissue biopsies. Applications include oncology research, forensics, fetal and stem cell biology, drug response, and downstream genomic analysis.
Menarini Silicon Biosystems, Inc. acquired in 2017 the CELLSEARCH® Circulating Tumor Cell System from Janssen Diagnostics, LLC. Marking Menarini-Silicon Biosystems’ first entry into the U.S. diagnostics market, the acquisition includes the CELLSEARCH® Circulating Tumor Cell Test — the first and only clinically validated blood test cleared by the U.S. Food and Drug Administration for detecting and enumerating circulating tumor cells (CTCs) to help manage patients with metastatic breast, prostate, and colorectal cancers. The test is also approved by the China Food and Drug Administration for use in monitoring metastatic breast cancer patients.
Working closely with clinical investigators and pharmaceutical companies, the acquisition is part of the company’s strategic objective to develop companion diagnostics that allow selecting patients more likely to respond to targeted drug treatments, and that accelerate the validation of personalized therapies.
For more information, please refer to www.siliconbiosystems.com.

Menarini Silicon Biosystems

Business Info

Contact Business

Company Summary

Similar Businesses Nearby

Competitive Landscape

Payments Accepted

Hours

Photos

Business Credit Report

Facebook

Twitter

Yelp

Customer Resources

Our Company

Our Network

Site Links